This milestone builds on Clarity's earlier receipt of 2 FTDs for the diagnostic 64 Cu-SAR-bisPSMA in patients with suspected metastasis of prostate cancer who are candidates for initial definitive ...
This milestone builds on Clarity's earlier receipt of an FTD for 64 Cu-SAR-bisPSMA in patients with suspected metastasis of prostate cancer who are candidates for initial definitive therapy [1]. These ...
LOS ANGELES, July 09, 2025 (GLOBE NEWSWIRE) -- Trethera Corporation ("Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, ...
Cancer Research UK-funded scientists have developed a new way to test the effectiveness of a drug for prostate cancer that has spread to the bone, which is currently incurable, according to research ...
NEW HAVEN, Conn., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Halda Therapeutics, a clinical-stage biotechnology company developing a novel class of therapies called RIPTAC™ Therapeutics, today announced that ...
Bayer has taken another step toward achieving its €3 billion peak sales estimate for androgen receptor inhibitor Nubeqa, scoring an FDA approval to expand its use to all patients with metastatic ...
TRE-515 has received FDA fast track designation for treating PSMA-positive mCRPC, aiming to accelerate its development and availability. The drug is being tested in combination with Pluvicto, a ...
HLD-0915 has received FDA fast track designation for mCRPC, expediting its development and review process to address unmet medical needs. Halda Therapeutics is conducting a phase 1/2 clinical trial to ...
“As a two-time prostate cancer survivor, I enjoy today as if it will be my last,” Jesse said. “I engage every man I meet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback